

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

POSITIVE PROFIT ALERT

This announcement is made by Jacobson Pharma Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform shareholders of the Company (“**Shareholders**”) and potential investors that, based on a preliminary review on the unaudited consolidated management accounts of the Group for the six months ended 30 September 2019 and the information currently available to the Board, the Group is expected to record an increase of over 30% in the consolidated profit attributable to shareholders of the Company for the six months ended 30 September 2019 as compared to that for the six months ended 30 September 2018.

The expected increase is mainly attributable to a steady growth of the Group’s generic drug business augmented with the sales revenue generated from newly in-licensed products, in addition to an uplifted sales performance on proprietary medicines. Operating leverage and financial savings derived from cost control measures also helped contribute to the expected increase in earnings. Fair value gain on redemption of convertible notes and investment properties of the Group is also expected to contribute, although to a lesser extent, to the increase in consolidated profit attributable to shareholders of the Company.

As at the date of this announcement, the consolidated results of the Group for the six months ended 30 September 2019 has not yet been finalized. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to unaudited consolidated management accounts of the Group for the six months ended 30 September 2019 and the information currently available to the Board. Such information has not been reviewed by the auditor of the Company. Further details of the Group's performance will be disclosed in the interim results announcement of the Company for the six months ended 30 September 2019 in accordance with the Listing Rules, which is expected to be published on 26 November 2019.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jacobson Pharma Corporation Limited
YIM Chun Leung
Executive Director and Company Secretary

Hong Kong, 13 November 2019

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung (also as Company Secretary) and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Wong Chi Kei, Ian as independent non-executive Directors.